登德里默:对阿尔茨海默病的专利
Shubhrat Maheshwari1, Aditya Singh2
1Faculty of Pharmaceutical Sciences, Rama University, Mandhana, Bithoor Road, Kanpur, Uttar Pradesh, 209217, India.
Recent patents on nanotechnology
|October 31, 2023
概括
丹德里默是一种有前途的纳米技术,可以通过血脑屏障传递药物,用于治疗像阿尔茨海默氏症这样的神经退行性疾病. 本综述涵盖了树枝状物专利和用于治疗这些疾病的临床试验.
科学领域:
- 神经科学是一个神经科学.
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经退行性疾病逐渐损害大脑细胞和神经连接.
- 粉样β (Aβ) 斑块和团是神经元死亡和疾病进展的关键标志.
- 血脑屏障 (BBB) 在治疗中枢神经系统疾病方面是一个重大挑战.
研究的目的:
- 审查 dendrimer 在治疗神经退行性疾病,特别是阿尔茨海默病 (AD) 中应用的现状.
- 突出树枝状体作为克服BBB的纳米技术,以有效的药物输送.
- 更新专利和临床试验文献,关于在AD中使用树枝状物.
主要方法:
- 科学文献的综述,重点关注树枝状分子药物递送系统.
- 分析与神经退行性疾病治疗中的树枝状体相关的专利和临床试验.
- 对各种树突类型的检查,包括PAMAM,PPI,PLL和碳烯树突.
主要成果:
- 登德里默表现出跨越BBB并增强大脑组织中药物吸收的显著潜力.
- 关键的树突类型 (PAMAM,PPI,PLL,carbosilane) 正在探索用于管理神经退行性疾病.
- 在美国,Starpharma的树枝体技术在2029年之前获得了专利保护.
结论:
- 登德里默为神经退行性疾病中的药物输送提供了一个多功能,生物相容和适应的平台.
- 进一步的研究和临床试验至关重要,以充分实现树枝状树脂对阿尔茨海默氏症和其他中枢神经系统疾病的治疗潜力.
- 基于纳米技术的树枝状物递送系统代表了对抗神经退行性疾病的前沿.
相关概念视频
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
01:26Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
01:30Dementia
120
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
120
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
131
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
131